glutathione disulfide has been researched along with Idiopathic Parkinson Disease in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 10 (41.67) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 2 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, F; Chen, YX; Fang, J; Shen, R; Zhang, B; Zhang, F; Zhao, Z | 1 |
| Andrade-da-Costa, BLDS; Augusto, RL; Cardoso, PRG; da Penha Gonçalves, LV; da Silva-Júnior, JC; de Albuquerque Rego, GN; de Souza Andrade, D; de Souza, IA; de Souza, RF; Dos Santos, ML; Medeiros-Linard, CFB; Mendonça, IP; Moreno, GMM; Peixoto, CA; Pereira, DD; Pereira, MC | 1 |
| Aureli, C; Cassano, T; Chichiarelli, S; Cocciolo, A; d'Erme, M; Fontana, M; Francioso, A; Gaetani, S; Mancini, P; Martire, S; Masci, A; Mosca, L; Romano, A | 1 |
| Ali, SJ; Rajini, PS | 1 |
| Gil, SJ; Kang, MJ; Koh, HC | 1 |
| Beal, MF; Calingasan, NY; Cormier, K; Ferrante, RJ; Smith, K; Wille, EJ; Yang, L | 1 |
| DiFrancisco-Donoghue, J; Elokda, A; Lamberg, EM; Werner, WG | 1 |
| Berg, D; Gaenslen, A; Gasser, T; Liepelt, I; Maetzler, W; Schmid, SP; Wurster, I | 1 |
| Dringen, R; Hirrlinger, J; Schulz, JB | 1 |
| Chen, CF; Ho, LT; Lin, AM | 1 |
| Jenner, P | 1 |
| Ehrhart, J; Zeevalk, GD | 2 |
| Amazzal, L; Bagrel, D; Lapôtre, A; Quignon, F | 1 |
| Day, BJ; Fulton, R; Huang, J; Liang, LP; Patel, M | 1 |
| Abe, T; Hamato, F; Saheki, M; Sasaki, K; Takahashi, S; Tohgi, H | 1 |
| Agid, Y; Daniel, S; Dexter, DT; Javoy-Agid, F; Jenner, P; Lees, AJ; Marsden, CD; Sian, J | 1 |
| Cohen, G; Farooqui, R; Kesler, N | 1 |
| DeMaggio, AJ; Havaich, MK; Juneau, PL; LeWitt, PA; Loeffler, DA | 1 |
| Jiang, DH; Lan, J | 1 |
| Andersen, JK; Forman, HJ; Greenamyre, JT; Jha, N; Jurma, O; Lalli, G; Liu, RM; Liu, Y; Pettus, EH | 1 |
| Adams, JD; Klaidman, LK; Miller, CA; Odunze, IN; Shen, HC | 1 |
| Cohen, G; Spina, MB | 1 |
| Perry, TL; Yong, VW | 1 |
1 review(s) available for glutathione disulfide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Oxidative stress in Parkinson's disease.
Topics: Aldehydes; Apoptosis; Corpus Striatum; Dopamine; Free Radicals; Glutathione Disulfide; Humans; Iron; Lipid Peroxidation; Mitochondria; Nerve Degeneration; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Peptide Hydrolases; Proteasome Endopeptidase Complex; Substantia Nigra; Superoxide Dismutase | 2003 |
23 other study(ies) available for glutathione disulfide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Naphthalimide Fluorescent Skeleton for Facile and Accurate Quantification of Glutathione.
Topics: Animals; Glutathione; Glutathione Disulfide; Mice; Naphthalimides; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Skeleton | 2023 |
Purified anacardic acids exert multiple neuroprotective effects in pesticide model of Parkinson's disease: in vivo and in silico analysis.
Topics: Anacardic Acids; Animals; Computer Simulation; Corpus Striatum; Glial Fibrillary Acidic Protein; Glutathione; Glutathione Disulfide; Humans; Interleukin-1beta; Lipid Peroxidation; Matrix Metalloproteinase 9; Mice; Neuroprotective Agents; Nitric Oxide; Oxidative Stress; Parkinson Disease; Parkinson Disease, Secondary; Pesticides; Tissue Inhibitor of Metalloproteinase-1; Transcription Factor RelA; Tyrosine 3-Monooxygenase | 2020 |
5-S-cysteinyldopamine neurotoxicity: Influence on the expression of α-synuclein and ERp57 in cellular and animal models of Parkinson's disease.
Topics: alpha-Synuclein; Animals; Biogenic Monoamines; Brain; Cell Line, Tumor; Disease Models, Animal; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Glutathione; Glutathione Disulfide; Humans; Male; Mice; Neuroblastoma; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Carbonylation; Protein Disulfide-Isomerases | 2014 |
Effect of monocrotophos, an organophosphorus insecticide, on the striatal dopaminergic system in a mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutathione Disulfide; Injections, Intraperitoneal; Insecticides; Lipid Peroxidation; Male; Mice; Monocrotophos; Neurons; Neurotoxins; Parkinson Disease; Reactive Oxygen Species; Tyrosine 3-Monooxygenase | 2016 |
Paraquat induces alternation of the dopamine catabolic pathways and glutathione levels in the substantia nigra of mice.
Topics: Animals; Dopamine; Glutathione Disulfide; Herbicides; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neurons; Paraquat; Parkinson Disease; Substantia Nigra; Tyrosine 3-Monooxygenase | 2009 |
Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 8-Hydroxy-2'-Deoxyguanosine; alpha-Synuclein; Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Creatine; Deoxyguanosine; Disease Models, Animal; Dopamine; Drug Therapy, Combination; Glutathione; Glutathione Disulfide; Huntington Disease; Lipid Peroxidation; Male; Malondialdehyde; Mice; Mice, Inbred C57BL; Neuroprotective Agents; Nitro Compounds; Parkinson Disease; Propionates; Rats; Rats, Inbred Lew; Tyrosine 3-Monooxygenase; Ubiquinone | 2009 |
Effects of exercise induced oxidative stress on glutathione levels in Parkinson's disease on and off medication.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Electrocardiography; Exercise; Glutathione; Glutathione Disulfide; Humans; Male; Middle Aged; Oxidative Stress; Parkinson Disease | 2010 |
Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases.
Topics: Aged; Aged, 80 and over; Dementia; Female; Glutathione; Glutathione Disulfide; Humans; Lewy Body Disease; Male; Middle Aged; Parkinson Disease | 2011 |
Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease.
Topics: Animals; Antioxidants; Astrocytes; Catalase; Catecholamines; Cells, Cultured; Culture Media, Conditioned; Dopamine; Dose-Response Relationship, Drug; Extracellular Space; Glutathione; Glutathione Disulfide; Hydrogen Peroxide; Oxidants; Oxidation-Reduction; Parkinson Disease; Rats; Rats, Wistar; Superoxide Dismutase | 2002 |
Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain.
Topics: Animals; Atmosphere Exposure Chambers; Brain; Buthionine Sulfoximine; Catalase; Disease Models, Animal; Drug Administration Routes; Female; Glutathione; Glutathione Disulfide; Glutathione Peroxidase; Hypoxia; Iron; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Superoxide Dismutase | 2002 |
Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures.
Topics: Animals; Antioxidants; Ascorbic Acid; Buthionine Sulfoximine; Chromans; Disulfides; Fluorescent Dyes; Glutathione; Glutathione Disulfide; Malonates; Mesencephalon; Mitochondria; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2003 |
Mangiferin protects against 1-methyl-4-phenylpyridinium toxicity mediated by oxidative stress in N2A cells.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Catalase; Cell Line, Tumor; Free Radical Scavengers; Glutathione; Glutathione Disulfide; Iron; Iron Metabolism Disorders; Mice; Nerve Degeneration; Neurons; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Parkinson Disease; RNA, Messenger; Superoxide Dismutase; Superoxide Dismutase-1; Xanthones | 2007 |
An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo.
Topics: Administration, Oral; Animals; Blood-Brain Barrier; Chronic Disease; Corpus Striatum; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Glutathione; Glutathione Disulfide; Half-Life; Injections, Subcutaneous; Male; Metalloporphyrins; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroprotective Agents; Oxidative Stress; Parkinson Disease | 2007 |
Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment.
Topics: Aged; Glutathione; Glutathione Disulfide; Humans; Levodopa; Middle Aged; Parkinson Disease; Vitamin E | 1995 |
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
Topics: Aged; Aged, 80 and over; Atrophy; Basal Ganglia Diseases; Brain; Brain Diseases; Female; Glutathione; Glutathione Disulfide; Humans; Huntington Disease; Male; Middle Aged; Nervous System Diseases; Parkinson Disease; Supranuclear Palsy, Progressive | 1994 |
Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow.
Topics: Animals; Benzylamines; Brain; Dopamine; Electron Transport; Glutathione; Glutathione Disulfide; Humans; Hydrogen Peroxide; Male; Mitochondria; Models, Neurological; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neurons; Oxygen Consumption; Parkinson Disease; Pyruvates; Rats; Rats, Sprague-Dawley; Succinates; Tyramine | 1997 |
Effects of enhanced striatal dopamine turnover in vivo on glutathione oxidation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Dopamine; Glutathione; Glutathione Disulfide; Levodopa; Male; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Substantia Nigra | 1994 |
Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Stem; Corpus Striatum; Glutathione; Glutathione Disulfide; Hydroxyl Radical; Iron; Iron, Dietary; Mice; Mice, Inbred C57BL; Neurodegenerative Diseases; Neurons; Parkinson Disease; Risk Factors | 1997 |
Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity. Implications for Parkinson's disease.
Topics: Animals; Down-Regulation; Doxycycline; Electron Transport Complex I; Glutathione; Glutathione Disulfide; NADH, NADPH Oxidoreductases; Oxidative Stress; Oxygen Consumption; Parkinson Disease; PC12 Cells; Rats; Reactive Oxygen Species; Substantia Nigra | 2000 |
Hydrogen peroxide removal and glutathione mixed disulfide formation during metabolic inhibition in mesencephalic cultures.
Topics: Amitrole; Animals; Antioxidants; Ascorbic Acid; Catalase; Cells, Cultured; Chromans; Energy Metabolism; Enzyme Inhibitors; Glutathione Disulfide; Hydrogen Peroxide; Malonates; Mesencephalon; Neurons; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species | 2001 |
Alzheimer's and Parkinson's disease. Brain levels of glutathione, glutathione disulfide, and vitamin E.
Topics: Aged; Alzheimer Disease; Brain; Glutathione; Glutathione Disulfide; Humans; Parkinson Disease; Vitamin E | 1991 |
Dopamine turnover and glutathione oxidation: implications for Parkinson disease.
Topics: Animals; Cerebral Cortex; Clorgyline; Corpus Striatum; Disease Models, Animal; Dopamine; Glutathione; Glutathione Disulfide; Male; Mice; Parkinson Disease; Reserpine | 1989 |
Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients.
Topics: Glutathione; Glutathione Disulfide; Glutathione Transferase; Humans; Ophthalmoplegia; Parkinson Disease; Substantia Nigra; Syndrome | 1986 |